(Corsee) Sanders Corazon - 05 Sep 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role
Director
Signature
/s/ Qing Nian, as Attorney-in-Fact
Issuer symbol
ONC
Transactions as of
05 Sep 2025
Net transactions value
-$483,218
Form type
4
Filing time
09 Sep 2025, 17:31:54 UTC
Previous filing
23 Jun 2025
Next filing
01 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sanders Corazon (Corsee) D. Director C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 09 Sep 2025 0001796536

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC American Depositary Shares Options Exercise $414,887 +2,665 $155.68 2,665 05 Sep 2025 Direct F1
transaction ONC American Depositary Shares Sale $898,105 -2,665 -100% $337.00 0 05 Sep 2025 Direct F1
holding ONC Ordinary Shares 57,226 05 Sep 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONC Share Option (Right to Buy) Options Exercise $0 -34,645 -100% $0.000000 0 05 Sep 2025 Ordinary Shares 34,645 $11.98 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share represents 13 Ordinary Shares.
F2 The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
F3 The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.